Brokerages Set Royalty Pharma plc (NASDAQ:RPRX) PT at $41.60

Shares of Royalty Pharma plc (NASDAQ:RPRX - Get Free Report) have received an average recommendation of "Buy" from the six ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $41.60.

Separately, TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th.

Institutional Investors Weigh In On Royalty Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. raised its position in shares of Royalty Pharma by 42.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company's stock worth $432,862,000 after acquiring an additional 5,069,127 shares in the last quarter. Norges Bank purchased a new position in shares of Royalty Pharma in the 4th quarter worth approximately $124,498,000. BNP Paribas Financial Markets purchased a new position in shares of Royalty Pharma in the 4th quarter worth approximately $41,959,000. AQR Capital Management LLC grew its position in shares of Royalty Pharma by 187.0% in the 4th quarter. AQR Capital Management LLC now owns 1,903,676 shares of the biopharmaceutical company's stock worth $48,563,000 after buying an additional 1,240,384 shares during the last quarter. Finally, Swedbank AB grew its position in shares of Royalty Pharma by 10.3% in the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock worth $310,308,000 after buying an additional 1,136,800 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

Remove Ads

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX traded down $0.56 during mid-day trading on Monday, reaching $33.21. The stock had a trading volume of 863,654 shares, compared to its average volume of 4,416,464. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The company has a market cap of $19.14 billion, a P/E ratio of 22.91, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. Royalty Pharma has a 1 year low of $24.05 and a 1 year high of $34.20. The business's 50 day moving average price is $30.57 and its 200 day moving average price is $28.32.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Research analysts expect that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.22 per share. The ex-dividend date is Friday, February 21st. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a yield of 2.65%. Royalty Pharma's payout ratio is 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.